2021 News

€4 million injection to help boost Mecwins’s position on the early diagnosis market

  • Mecwins has signed a financial agreement with its investor partners CRB BIO II, Masela Inversiones and Progenika-Grifols, which will allow it to develop new early detection prototypes based on ultra-sensitive AVAC technology.
  • This will enable the creation of new routes for the clinical diagnosis and treatment of several diseases in their early stages.
  • Mecwins General Manager Óscar Ahumada, says that the agreement “strengthens and bolsters our financial position and recognises the value we have created to date.”

(Madrid, 8 June 2021). Spanish biotech company Mecwins has signed a strategic funding agreement with current partners and new investors worth €4 million, enabling it to develop new prototypes based on its ultra-sensitive AVAC protein detection platform and fast-track its entry into the Life and Health Sciences market.

The AVAC platform uses innovative technology that had proved effective in detecting extremely important biomarkers, such as cytokins, inflammation markers and cancer markers, among others, at very low blood levels, for the early diagnosis of a range of diseases.

Under the agreement, signed with top investors CRB BIO II and Masela Inversiones, along with molecular biology test developers Progenika-Grifols, Mecwins will strengthen its research team and develop new clinical trials to back the diagnostic capacity of its AVAC technology, greatly more sensitive than other alternatives on the market. This will make it possible to create new routes for the clinical diagnosis and treatment of several diseases in their initial stages, thus improving patients’ quality of life and expectations.

Ahumada stated that the agreement “strengthens and bolsters our financial position and recognises the value we have created to date.” “With the resources we now have, we will be able to fast-track the growth and commercial development of the company. The coming months are going to bring huge transformation for Mecwins”, he added.

The capital increase is a new step in the Mecwins growth strategy, after recently agreeing to partner with the Ramón y Cajal Institute for Health Research (IRYCIS) to develop new haematology and autoimmune disease markers. The alliance comes on the heels of the strategic partnership between Mecwins and Quidel Corporation, the leading manufacturer of diagnostic solutions at point of care (POC). It aims to develop a new test platform based on its AVAC technology, which can detect and quantify biomarkers at much lower levels than currently available diagnostic tests used outside the laboratory.

Read the full notice in “360Dx”
Read the full notice in “Capital Riesgo”
Read the full notice in “Portales Médicos”
About Mecwins

Mecwins is a spin-off of the CSIC Micro and Nanotechnology Institute, based in Tres Cantos, founded in 2008 by Dr Javier Tamayo and Dr Montserrat Calleja, leaders of the IMM-CSIC bionanomechanics group. Mecwins’s mission is to develop and bring to market technology for ultrasensitive detection of proteins and RNA and DNA biomarkers. The Mecwins team boasts physicians, mathematicians, chemists, biologists and engineers, all with extensive know-how and international experience.

Mecwins high-performance ultra-sensitive AVAC technology combines plasmonic technology, a cutting-edge optical technique used for the early detection of a range of illnesses, and immune testing for multiple detection of proteins and RNA and DNA biomarkers in levels of one femtogram (10 -15 g) per ml and less.